https://www.selleckchem.com/pr....oducts/bsj-4-116.htm
2 % vs. 15.8 % vs. 16.6 %, respectively, P = 0.01. CD4 cell count 200 cell/mm was associated with the lowest probability of VS (91.5 %, P 0.001) and the highest probability of VR (20.7 %, P = 0.008) compared to higher CD4 levels. Multivariable Cox-regression confirmed the negative role of high pre-therapy viremia and low CD4 cell count on VS, but not on VR. Forty-three (5.3 %) patients experienced VF (raltegravir 30; elvitegravir 9; dolutegravir 4). Patients failing dolutegravir did not harbor any resistance mutation either
Like
Comment
Share
